DK0763128T3 - Process for the production of heterologous bispecific antibodies - Google Patents

Process for the production of heterologous bispecific antibodies

Info

Publication number
DK0763128T3
DK0763128T3 DK95919458T DK95919458T DK0763128T3 DK 0763128 T3 DK0763128 T3 DK 0763128T3 DK 95919458 T DK95919458 T DK 95919458T DK 95919458 T DK95919458 T DK 95919458T DK 0763128 T3 DK0763128 T3 DK 0763128T3
Authority
DK
Denmark
Prior art keywords
bispecific antibodies
antibodies
protein
binding site
affinity
Prior art date
Application number
DK95919458T
Other languages
Danish (da)
Inventor
Horst Lindhofer
Stephan Thierfelder
Original Assignee
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt
Application granted granted Critical
Publication of DK0763128T3 publication Critical patent/DK0763128T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention pertains to a method for producing heterologous bispecific antibodies. The object of the invention is a method designed to yield heterologous bispecific antibodies with a high level of purity. This is attained by producing a quadroma fused from hybridomas, one of which produces antibodies that have an affinity to the binding site of protein A and the other of which produces antibodies that have a weaker or no affinity to the binding site of protein A; by propagating and cultivating the quadromas as usual, and by eluting the bsAk in a pH range at least 0.5 units above the pH at which the antibodies with greater affinity to the binding site of protein A are still bonded.
DK95919458T 1994-06-03 1995-05-16 Process for the production of heterologous bispecific antibodies DK0763128T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4419399A DE4419399C1 (en) 1994-06-03 1994-06-03 Process for the preparation of heterologous bispecific antibodies
PCT/EP1995/001850 WO1995033844A1 (en) 1994-06-03 1995-05-16 Method for producing heterologous bispecific antibodies

Publications (1)

Publication Number Publication Date
DK0763128T3 true DK0763128T3 (en) 2000-04-10

Family

ID=6519692

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95919458T DK0763128T3 (en) 1994-06-03 1995-05-16 Process for the production of heterologous bispecific antibodies

Country Status (7)

Country Link
EP (1) EP0763128B1 (en)
JP (1) JP3400457B2 (en)
AT (1) ATE187176T1 (en)
DE (3) DE122009000068I2 (en)
DK (1) DK0763128T3 (en)
NL (1) NL300419I1 (en)
WO (1) WO1995033844A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19634159C1 (en) * 1996-08-23 1997-09-25 Gsf Forschungszentrum Umwelt Hybrid cells prepared by fusing malignant B cells with hybridoma that expresses antibodies
DE19649223C2 (en) * 1996-09-03 1998-07-30 Gsf Forschungszentrum Umwelt Destruction of contaminating tumor cells in stem cell transplants with bispecific antibodies
DE19710497C2 (en) * 1996-09-03 1998-07-09 Gsf Forschungszentrum Umwelt Use bi- and trispecific antibodies to induce tumor immunity
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
WO2005035753A1 (en) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
CN101939424B (en) 2007-12-05 2016-12-28 中外制药株式会社 Anti-NR10 antibody and application thereof
NO2708559T3 (en) 2008-04-11 2018-08-25
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI646193B (en) 2009-03-19 2019-01-01 中外製藥股份有限公司 Antibody constant region alteration
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2241576A1 (en) 2009-04-17 2010-10-20 Trion Pharma Gmbh Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
EP2445936A1 (en) * 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
WO2011078332A1 (en) 2009-12-25 2011-06-30 中外製薬株式会社 Polypeptide modification method for purifying polypeptide multimers
EP2530109A4 (en) 2010-01-29 2013-08-28 Toray Industries Polylactic acid-based resin sheet
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
BR112013012213A2 (en) 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha multi-specific antigen-binding molecules having an alternative function to the function of factors viii, ix ex of blood coagulation, and bispecific antibody, their uses in the prevention or treatment of hemorrhage, nucleic acid, vector, cell, method to produce the aforementioned binding molecules, pharmaceutical composition and kit
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
BR112013013311A2 (en) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd cytotoxicity-inducing therapeutic agent
EP2524699A1 (en) 2011-05-17 2012-11-21 Trion Research GmbH Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
EP2709655B1 (en) 2011-05-17 2018-11-14 Trion Research GmbH Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
TWI687441B (en) 2011-06-30 2020-03-11 中外製藥股份有限公司 Heterodimerized polypeptide
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
EP2578230A1 (en) 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
KR102273985B1 (en) 2012-08-24 2021-07-06 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc region variant
JP2015529236A (en) 2012-09-25 2015-10-05 グレンマーク ファーマシューティカルズ， エセ．アー． Purification of heterodimeric immunoglobulin
JP6433297B2 (en) 2012-12-27 2018-12-05 中外製薬株式会社 Heterodimerized polypeptide
RU2730594C2 (en) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Method of producing a polypeptide heteromultiters
AU2014343636A1 (en) 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
WO2015068847A1 (en) 2013-11-11 2015-05-14 中外製薬株式会社 Antigen-binding molecule containing modified antibody variable region
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PL3263132T3 (en) 2015-02-27 2024-04-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
JP6925278B2 (en) 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response
EP3378487B1 (en) 2015-11-18 2022-03-16 Chugai Seiyaku Kabushiki Kaisha Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2019244973A1 (en) 2018-06-20 2019-12-26 中外製薬株式会社 Method for activating immune response of target cell and composition therefor
EP4023230A4 (en) 2019-06-05 2023-11-15 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule
CR20220049A (en) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
MX2022000744A (en) 2019-07-18 2022-04-18 Lindis Blood Care Gmbh Removal of tumor cells from intraoperative autologous blood salvage by using a trifunctional antibody.
KR20240035914A (en) 2019-12-27 2024-03-18 추가이 세이야쿠 가부시키가이샤 Anti-ctla-4 antibody and use thereof
IL296802A (en) 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd Method for producing multispecific antigen-binding molecules
JPWO2022025220A1 (en) 2020-07-31 2022-02-03
US20230416371A1 (en) 2020-08-28 2023-12-28 Chugai Seiyaku Kabushiki Kaisha Heterodimer fc polypeptide
EP3991796A1 (en) 2020-10-27 2022-05-04 Lindis Blood Care GmbH An ex vivo method for removal of tumor cells from intra-operatively salvaged blood
WO2022270612A1 (en) 2021-06-25 2022-12-29 中外製薬株式会社 Use of anti-ctla-4 antibody
KR102690141B1 (en) 2021-06-25 2024-07-30 추가이 세이야쿠 가부시키가이샤 Anti-CTLA-4 antibody
EP4116330A1 (en) 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
US20240239916A1 (en) 2021-07-05 2024-07-18 Trion Research Gmbh Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
WO2023053282A1 (en) 2021-09-29 2023-04-06 中外製薬株式会社 Cytotoxicity-inducing therapeutic agent for use in treatment of cancer
CA3233924A1 (en) 2021-10-08 2023-04-13 Kengo ARAI Method for preparing prefilled syringe formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies

Also Published As

Publication number Publication date
NL300419I1 (en) 2010-01-04
JP3400457B2 (en) 2003-04-28
JPH09506001A (en) 1997-06-17
WO1995033844A1 (en) 1995-12-14
DE59507342D1 (en) 2000-01-05
DE122009000068I2 (en) 2011-06-16
DE122009000068I1 (en) 2010-05-27
DE4419399C1 (en) 1995-03-09
ATE187176T1 (en) 1999-12-15
EP0763128B1 (en) 1999-12-01
EP0763128A1 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
DK0763128T3 (en) Process for the production of heterologous bispecific antibodies
ATE553125T1 (en) PRODUCTION OF A MULTIMERIC PROTEIN BY CELL FUSION PROCESS
DE69126281D1 (en) Process for the production of antibodies
ATE153332T1 (en) METHOD FOR PRODUCING OXETANONES
DK1167537T3 (en) Process for producing a monoclonal antibody
DE3580654D1 (en) HUMAN HYBRIDOMFUSION PARTNER FOR THE PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES.
ATE330003T1 (en) RECOMBINANT STABLE CELL CLONE, ITS PRODUCTION AND USE
DE3581288D1 (en) ANTILEISHMANIA MONOCLONAL ANTI-BODIES, THESE ANTI-BODY ELIMINATING HYBRIDOMAS, LEISHMANIA-ANTIGENS RECOGNIZED BY THESE ANTI-BODIES, METHODS FOR THE PRODUCTION AND USE OF THESE MONOCLONAL ANTI-ANODIERS AND ANTIBODIES.
NO172596C (en) APOLIPOPROTEIN B-SPECIFIC MONOCLONAL ANTIBODIES PRODUCED BY TWO NEW HYBRIDOMS, USE OF THESE AND DIAGNOSTIC SYSTEMS INCLUDING THESE
DK461787A (en) PROCEDURE FOR SELECTING TO INCREASE THE QUANTITY RELATIONSHIP BETWEEN SOME MAIN COMPONENTS OF ANTIBIOTIC A / 16686 COMPLEX
DK56893D0 (en) PROCEDURE FOR THE PREPARATION OF A SPRING INSTALLATION
ATE366120T1 (en) HIGHLY EFFICIENT TISSUE-SPECIFIC SYSTEM FOR PROVIDING COMPOUNDS USING A STREPTAVIDIN PROTEIN A FUSION PROTEIN
GB9319877D0 (en) Novel hybridoma & monoclonal antibodies produced thereby
DE3576359D1 (en) METHOD FOR PRODUCING TUMOR-SPECIFIC MONOCLONAL ANTIBODY-PRODUCING HYBRIDOMA CELLS.
DK1095141T3 (en) Process for producing a peptide having a pI value above 8 or below 5
DE69811899D1 (en) METHOD FOR PRODUCING METHYL METHACRYLATE
DK1546185T3 (en) Process for the production of growth hormone and its antagonist with lower levels of isoform impurities thereof
EA199700310A1 (en) BIOLOGICAL METHOD OF OBTAINING COMPOUNDS OF DIPEPTID NATURE
ATE367827T1 (en) METHOD FOR REDUCING THE IMMUNOGENICITY OF THE VARIABLE REGIONS OF ANTIBODIES
ATE100420T1 (en) METHOD OF PRODUCTION OF PHOSPHATES BY MELTING.
BE902877A (en) HYBRIDOME CAPABLE OF PRODUCING A MONOCLONAL ANTIBODY TO BOVINE LACTOFERRIN
DK378984D0 (en) PROCEDURE FOR MANUFACTURING ARPHAMENINE IN HIGH YIELD
EP0287012A3 (en) Anti-r-binder monoclonal antibody, process for preparing the same and application of the same